Drug Price Trends for DIFLUNISAL

Average Pharmacy Cost for DIFLUNISAL

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
DIFLUNISAL 500 MG TABLET	14539-0673-01	0.94787	EACH	2024-12-18
DIFLUNISAL 500 MG TABLET	00093-9222-05	0.94787	EACH	2024-12-18
DIFLUNISAL 500 MG TABLET	00093-9222-06	0.94787	EACH	2024-12-18
DIFLUNISAL 500 MG TABLET	14539-0673-06	0.94787	EACH	2024-12-18
DIFLUNISAL 500 MG TABLET	00093-9222-01	0.94787	EACH	2024-12-18

DIFLUNISAL Market Analysis and Financial Projection

Market Analysis and Price Projections for Diflunisal

Introduction to Diflunisal

Diflunisal is a nonsteroidal anti-inflammatory drug (NSAID) primarily used for pain relief and reducing inflammation in conditions such as arthritis, osteoarthritis, and rheumatoid arthritis. Here’s a comprehensive analysis of the market trends, projections, and pricing for diflunisal.

Global Market Size and Growth

The global diflunisal market is anticipated to experience significant growth over the coming years. As of 2023, the market was valued at US$ 338 million and is expected to reach US$ 482.6 million by 2030, with a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period of 2024-2030[1].

Another projection suggests that the market could reach USD 300 million by 2025, driven by the increasing prevalence of chronic pain conditions and the growing geriatric population[3].

Market Segmentation

The diflunisal market is segmented based on several criteria:

By Type

• The market is segmented into tablets and capsules. These formulations are designed to meet different patient needs and preferences[1][4].

By Application

• The primary applications include rheumatoid arthritis, osteoarthritis, sprain, and other inflammatory conditions. The growing demand for pain management medications in these areas is a key driver of market growth[1][4].

By Region

• The market is geographically segmented into North America, Europe, Asia-Pacific, South America, and the Middle East & Africa. Each region has its own set of drivers and restraints, with North America and Europe being significant markets due to their well-established healthcare infrastructures and high prevalence of chronic pain conditions[1][3][4].

Regional Market Analysis

North America

• The United States and Canada are the key markets in this region, driven by the high prevalence of chronic pain conditions and a well-established healthcare infrastructure[3].

Europe

• Countries such as Germany, France, the UK, Italy, and Russia are major markets, with growth attributed to the increasing elderly population and rising awareness about chronic pain management[3].

Asia-Pacific

• This region includes countries like China, Japan, South Korea, India, Australia, and others. The market here is driven by increasing healthcare expenditure, a growing geriatric population, and the rising prevalence of chronic pain disorders[3].

Latin America

• Mexico, Brazil, Argentina, and Colombia are key markets, with growth driven by the growing demand for pain management medications and improving access to healthcare services[3].

Middle East & Africa

• Turkey, Saudi Arabia, UAE, and other countries in this region are experiencing market growth due to the increasing prevalence of chronic pain conditions and growing healthcare infrastructure[3].

Price Projections and Affordability

The cost of diflunisal varies based on the dosage and quantity. For example, a 30-day supply of 60 tablets of 500 mg diflunisal can cost around $49.17, with the cost per unit decreasing as the quantity increases[2].

• 60 tablets: $49.17 (approximately $0.82 per unit)
• 100 tablets: $75.62 (approximately $0.76 per unit)
• 500 tablets: $340.12 (approximately $0.68 per unit)[2].

Discount programs and patient assistance plans can further reduce the cost, making the medication more affordable for patients.

Market Trends and Drivers

Several trends are driving the growth of the diflunisal market:

Increasing Prevalence of Chronic Pain Conditions

• The rising incidence of arthritis and other inflammatory diseases is a significant driver of market growth[1][3].

Growing Geriatric Population

• The increasing elderly population worldwide is contributing to the demand for pain management medications like diflunisal[3].

Innovative Formulations

• The development of extended-release formulations and other innovative drug forms is improving patient compliance and convenience, further driving market growth[3].

Research and Development

• Major pharmaceutical companies are investing in research and development to introduce new and improved formulations of diflunisal, which is expected to propel market growth[3].

Competitive Landscape

The diflunisal market is competitive, with key players such as:

• Teva
• Heritage Pharma
• Zydus Pharms
• Juhua Group
• Zhengzhou Taifeng
• Luoxin Pharmaceutical
• Shapuaisi Pharma
• Yuanlijian Yaoye
• Zhongsheng Pharmaceutical

These companies are leading in terms of market growth, innovation, and sales revenue, and continue to invest in research and development to expand their market presence[1][3].

Challenges and Opportunities

Challenges

• Despite the growth potential, the market faces challenges such as side effects associated with NSAIDs, regulatory hurdles, and competition from other pain management medications[4].

Opportunities

• Opportunities include strategic collaborations between pharmaceutical companies, expanding distribution networks, and launching promotional campaigns to target key consumer segments such as the elderly population and individuals with chronic pain conditions[3].

Key Takeaways

• The global diflunisal market is expected to grow significantly, driven by the increasing prevalence of chronic pain conditions and the growing geriatric population.
• The market is segmented by type (tablets and capsules), application (rheumatoid arthritis, osteoarthritis, etc.), and region.
• Key regions include North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
• The cost of diflunisal can be managed through discount programs and patient assistance plans.
• Major pharmaceutical companies are driving innovation and market growth through research and development.

FAQs

1. What is diflunisal used for? Diflunisal is used to relieve pain and reduce inflammation in conditions such as arthritis, osteoarthritis, and rheumatoid arthritis.

2. What is the projected market size of diflunisal by 2030? The global diflunisal market is expected to reach US$ 482.6 million by 2030[1].

3. What are the key drivers of the diflunisal market? Key drivers include the increasing prevalence of chronic pain conditions, the growing geriatric population, and the development of innovative formulations[1][3].

4. Which regions are significant for the diflunisal market? North America, Europe, Asia-Pacific, South America, and the Middle East & Africa are significant regions for the diflunisal market[1][3].

5. How can patients reduce the cost of diflunisal? Patients can reduce the cost of diflunisal through discount programs, patient assistance plans, and using discount cards accepted at major pharmacies[2].

Cited Sources

1. Global Diflunisal Market Research Report 2024 - QYResearch
2. Diflunisal Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
3. Diflunisal Market Trends: Focusing on Diflunisal Market Insight and Forecast Analysis (2024 - 2031) - Hashnode
4. Global Diflunisal Market Size, Trends and Projections - Market Research Intellect